PCOS Renamed to PMOS to Reflect Broader Health Risks

Key Points

• • The World Health Organization estimates that 10%–13% of reproductive-age women are affected by PCOS, with nearly 70% remaining undiagnosed.
  • Researchers published a proposal in The Lancet to rename polycystic ovary syndrome (PCOS) as polyendocrine metabolic ovarian syndrome (PMOS).
  • Experts say the new terminology better reflects the endocrine, metabolic, reproductive, and mental health impacts linked to the condition.
  • Clinicians hope the updated name will improve diagnosis, multidisciplinary care, research funding, and patient awareness.
  • To know about the latest updates in women’s health, register for #HerHealth2026

PCOS Renamed to PMOS to Improve Clinical Understanding

A major shift in women’s health terminology is reshaping how clinicians understand and manage one of the world’s most common endocrine disorders. Researchers and global women’s health experts have officially proposed renaming polycystic ovary syndrome (PCOS) as polyendocrine metabolic ovarian syndrome (PMOS) to better represent the condition’s broad systemic effects.

Published in The Lancet, the proposal was led by Dr. Helena Teede, an endocrinologist and professor of women’s health at Monash University. The name change follows 14 years of international collaboration involving 56 patient advocacy and professional organizations.

Why Was PCOS Renamed to PMOS?

The term “polycystic ovary syndrome” has long been criticized for focusing narrowly on ovarian cysts, despite many patients never developing true ovarian cysts. According to specialists, the previous terminology often contributed to delayed diagnosis, misunderstanding, and fragmented treatment strategies.

What Does PMOS Mean

The new name highlights three major components of the condition:

• Polyendocrine: Reflects widespread hormonal dysfunction
• Metabolic: Acknowledges insulin resistance, obesity risk, and type 2 diabetes association
• Ovarian Syndrome: Retains the reproductive health connection

Experts say PMOS better captures the disorder’s links to infertility, cardiovascular disease, metabolic syndrome, depression, anxiety, sleep apnea, acne, hair loss, and excess androgen activity.

Dr. Andrea Dunaif from the Icahn School of Medicine at Mount Sinai noted that research since the 1980s has consistently connected the disorder with insulin resistance and broader metabolic dysfunction, not solely reproductive symptoms.

Clinical Implications for Healthcare Professionals

How Could the PMOS Name Change From PCOS Impact Patient Care?

Healthcare leaders believe the revised terminology may strengthen multidisciplinary collaboration between endocrinologists, gynecologists, dermatologists, psychiatrists, fertility specialists, and primary care clinicians.

Dr. Alla Vash-Margita from the Yale School of Medicine emphasized that the previous name created stigma and misconceptions, with many patients incorrectly assuming they had dangerous ovarian cysts.

Clinicians are also hopeful that recognizing PMOS as a multisystem disorder could increase insurance coverage, research funding, and development of targeted therapies for women’s metabolic and mental health concerns.

When Should Patients Be Evaluated for PMOS?

Experts recommend hormonal evaluation for patients presenting with:

• Fewer than eight menstrual cycles annually
• Menstrual cycles lasting longer than 40 days
• Acne, hirsutism, or female-pattern hair loss
• Weight gain or insulin resistance
• Fertility difficulties

Current treatment strategies focus largely on symptom management through lifestyle interventions, weight management, hormonal therapies, fertility treatments, and emerging metabolic therapies such as GLP-1 receptor agonists.

Specialists stress that individualized and coordinated care remains central to long-term PMOS management, particularly as awareness of the condition’s psychological and metabolic burden continues to expand.

Source:

The Lancet